Finding New Solutions We have a strong and varied R&D pipeline, focused on five therapeutic areas: immunoglobulins, transplant and immunology, hematology, cardiovascular and renal, and vaccines. In FY2025 alone we invested $1.4 billion in R&D. During this period, we achieved 56 regulatory approvals, comprising 43 new product registrations and 13 new indications – providing more treatment options for patients with serious diseases. In FY2025, we progressed 59 clinical trials across clinical, registration and post launch stages. When we are developing new treatments, we aim to create enduring impact for patients and public health. That is why it is important that our programs are informed by patient insights and are representative of the diverse people and communities affected by these diseases and conditions. In FY2025, more than 33,000 patients participated in our clinical trials. At CSL, we are dedicated to advancing global health through groundbreaking research and innovative treatments. Each year, our scientists and medical professionals publish numerous peer-reviewed papers, contributing valuable knowledge to the medical community and beyond. In FY2025, we published over 100 manuscripts in peer-reviewed journals that adhere to the stringent standards set by the International Committee of Medical Journal Editors (ICMJE). In order to ensure the public can engage with and benefit from the latest research we routinely prepare lay language summaries of clinical studies. The information is presented in a way that is easy to understand, avoiding technical jargon. These summaries are available in multiple languages to ensure that the general public can access and understand the information. In the past year we prepared lay summaries for 10 clinical studies. Number of clinical trials underway in FY2025, across clinical, registration and post‑launch stages Immunoglobulins 8 Hematology 15 Cardiovascular and renal 12 Transplant and immunology 14 Vaccines 10 59 “ We sometimes romanticise scientific breakthroughs, imagining that they occur because of a single genius or a singular lightbulb moment. But the reality of science looks more like a constellation than one shining star. It generally takes multiple lines of inquiry and the layered accumulation of knowledge and experience – and a whole lot of perseverance.” Dr Bill Mezzanotte, Executive Vice President, Head of Research & Development, CSL $1.4b invested in R&D in FY2025 19 Limited Our Impact 2025 About CSL From our CEO Lifesaving Medicines Healthier Communities Legacy Science and Medicine
RkJQdWJsaXNoZXIy MjE2NDg3